MBX
MBX Biosciences, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$61.72
+0.49%Aug 27, 2026, 12:00 UTC
MBX Biosciences dosed the first patient in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for adults with hypoparathyroidism, building on positive Phase 2 results and durable one-year clinical benefit.
Source:Aug 6, 2026, 00:00 UTC
MBX Biosciences reported a net loss of $37.1 million for Q2 2026, compared to a net loss of $19.4 million in Q2 2025, with cash and marketable securities of $418.6 million as of June 30, 2026.
Jul 13, 2026, 20:15 UTC
MBX Biosciences appointed Steve Hoerter as Chairman and CEO, replacing Kent Hawryluk, and appointed John Smither as CFO, effective immediately.
Source:Jun 12, 2026, 14:43 UTC
MBX Biosciences Inc. reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism.
Source: